Table 3. Functional assessment and echocardiographic indicators at week 0 and 24 in the macitentan combination group.
| Parameters | Baseline | After treatment | Statistic | P |
|---|---|---|---|---|
| WHO-FC | Z=−3.76 | <0.001 | ||
| I | 0 | 1 | ||
| II | 2 | 14 | ||
| III | 16 | 8 | ||
| IV | 5 | 0 | ||
| 6MWD (m) | 290.00 (180.00, 328.00) | 400.00 (300.00, 465.00) | Z=−4.11 | <0.001 |
| NT-proBNP (mmHg) | 1,127.00 (269.30, 2,736.00) | 205.00 (65.27, 524.80) | Z=−3.74 | <0.001 |
| RVD (mm) | 42.30±4.42 | 38.22±6.05 | t=3.46 | 0.002 |
| RAD (mm) | 45.09±5.56 | 40.30±5.80 | t=3.69 | 0.001 |
| AAO (mm) | 31.43±4.42 | 32.26±3.06 | t=−1.12 | 0.28 |
| LVEDd (mm) | 42.00 (39.00, 44.00) | 46.00 (42.00, 48.00) | Z=−3.83 | <0.001 |
| sPAP (mmHg) | 85.04±19.82 | 61.17±23.73 | t=6.88 | <0.001 |
| TRPG (mmHg) | 80.30±20.98 | 57.17±23.53 | t=6.54 | <0.001 |
| TAPSE (mm) | 17.72±3.36 | 19.54±2.76 | t=−3.12 | 0.005 |
| ALT (U/L) | 16.60 (10.50, 26.10) | 17.40 (9.60, 22.00) | Z=−1.00 | 0.32 |
| AST (U/L) | 19.70 (14.90, 29.70) | 19.20 (17.30, 22.60) | Z=−0.82 | 0.41 |
| Scr (µmol/L) | 59.70 (51.20, 75.60) | 62.40 (54.00, 69.80) | Z=−0.23 | 0.82 |
| Hb (g/L) | 123.00 (113.00, 138.00) | 119.00 (112.00, 128.00) | Z=−0.62 | 0.54 |
Data are presented as numbers, mean ± standard deviation or median (interquartile range). WHO-FC, World Health Organization functional class; 6MWD, 6-minute walk distance; NT-proBNP, N-terminal pro-brain natriuretic peptide; RVD, right ventricular diameter; RAD, right atrial diameter; AAO, ascending aortic root inner diameter; LVEDd, left ventricular end-diastolic diameter; sPAP, systolic pulmonary artery pressure; TRPG, tricuspid regurgitation pressure gradient; TAPSE, tricuspid annular plane systolic excursion; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Scr, serum creatinine; Hb, hemoglobin.